Henry Schein (NASDAQ:HSIC) CEO Stanley Bergman Sells 38,346 Shares

Henry Schein, Inc. (NASDAQ:HSIC) CEO Stanley Bergman sold 38,346 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $81.01, for a total value of $3,106,409.46. Following the transaction, the chief executive officer owned 427,615 shares of the company’s stock, valued at approximately $34,641,091.15. This represents a 8.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Henry Schein Trading Up 1.1%

NASDAQ:HSIC traded up $0.92 during trading hours on Friday, hitting $82.39. The company had a trading volume of 1,562,469 shares, compared to its average volume of 1,447,010. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.38 and a quick ratio of 0.79. The stock has a 50-day moving average price of $77.75 and a 200 day moving average price of $72.04. The company has a market capitalization of $9.70 billion, a PE ratio of 25.20, a price-to-earnings-growth ratio of 2.43 and a beta of 0.88. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $89.29.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The business had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.34 billion. During the same period in the prior year, the business earned $1.19 EPS. The company’s revenue for the quarter was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, equities research analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Compound Planning Inc. bought a new position in Henry Schein during the fourth quarter valued at approximately $275,000. Corient Private Wealth LLC lifted its holdings in shares of Henry Schein by 5.4% during the 4th quarter. Corient Private Wealth LLC now owns 37,019 shares of the company’s stock valued at $2,798,000 after buying an additional 1,906 shares during the period. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Henry Schein by 7.8% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 4,318 shares of the company’s stock valued at $326,000 after buying an additional 312 shares during the period. State of Tennessee Department of Treasury boosted its stake in shares of Henry Schein by 411.7% in the 4th quarter. State of Tennessee Department of Treasury now owns 75,773 shares of the company’s stock worth $5,719,000 after buying an additional 60,965 shares during the last quarter. Finally, Mackenzie Financial Corp grew its holdings in shares of Henry Schein by 202.4% in the fourth quarter. Mackenzie Financial Corp now owns 10,933 shares of the company’s stock worth $834,000 after acquiring an additional 7,318 shares during the period. 96.62% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on HSIC. UBS Group increased their price objective on Henry Schein from $79.00 to $87.00 and gave the stock a “neutral” rating in a report on Wednesday. Leerink Partners upped their target price on shares of Henry Schein from $75.00 to $87.00 and gave the stock a “market perform” rating in a research report on Tuesday. Barclays assumed coverage on shares of Henry Schein in a research report on Monday, December 8th. They set an “overweight” rating and a $86.00 price target for the company. Barrington Research set a $97.00 price objective on shares of Henry Schein and gave the stock an “outperform” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. raised their target price on shares of Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a research note on Wednesday. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $85.58.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.